Drug therapy in patients with Parkinson’s disease

Translational Neurodegeneration

Thomas Müller¹ 

[1] Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Gartenstr. 1, 13088, Berlin, Germany

关键词: drug therapy;    non motor features;    Parkinson’s disease;    Motor symptoms;   

Others  :  838983
DOI  :  10.1186/2047-9158-1-10

 received in 2012-01-11, accepted in 2012-05-24,  发布年份 2012

【 摘 要 】

Parkinson`s disease (PD) is a progressive, disabling neurodegenerative disorder with onset of motor and non-motor features. Both reduce quality of life of PD patients and cause caregiver burden. This review aims to provide a survey of possible therapeutic options for treatment of motor and non motor symptoms of PD and to discuss their relation to each other. MAO-B-Inhibitors, NMDA antagonists, dopamine agonists and levodopa with its various application modes mainly improve the dopamine associated motor symptoms in PD. This armentarium of PD drugs only partially influences the onset and occurrence of non motor symptoms. These PD features predominantly result from non dopaminergic neurodegeneration. Autonomic features, such as seborrhea, hyperhidrosis, orthostatic syndrome, salivation, bladder dysfunction, gastrointestinal disturbances, and neuropsychiatric symptoms, such as depression, sleep disorders, psychosis, cognitive dysfunction with impaired execution and impulse control may appear. Drug therapy of these non motor symptoms complicates long-term PD drug therapy due to possible occurrence of drug interactions, - side effects, and altered pharmacokinetic behaviour of applied compounds. Dopamine substituting compounds themselves may contribute to onset of these non motor symptoms. This complicates the differentiation from the disease process itself and influences therapeutic options, which are often limited because of additional morbidity with necessary concomitant drug therapy.

【 授权许可】

   
2012 Mueller; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Przuntek H, Müller T, Riederer P: Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm 2004, 111:201-216.
• [2]Riederer P, Lachenmayer L, Laux G: Clinical applications of MAO-inhibitors. Curr Med Chem 2004, 11:2033-2043.
• [3]Parkinson Study Group: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group N Engl J Med 1993, 328:176-183.
• [4]Parkinson Study Group: A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004, 61:561-566.
• [5]Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al.: A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009, 361:1268-1278.
• [6]Müller T: Dopaminergic substitution in Parkinson's disease. Expert Opin Pharmacother 2002, 3:1393-1403.
• [7]Müller T, Fritze J: Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clin Neuropharmacol 2003, 26:109-111.
• [8]Stocchi F, Giorgi L, Hunter B, Schapira AH: PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. Mov Disord 2011, 26:1259-1265.
• [9]Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, et al.: Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology 2011, 77:759-766.
• [10]Müller T, Kuhn W, Schulte T, Przuntek H: Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease. Neurosci Lett 2003, 339:25-28.
• [11]Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M: Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004, 75:141-143.
• [12]Crosby NJ, Deane KH, Clarke CE: Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev 2003.
• [13]Tarsy D: Initial treatment of Parkinson's disease. Curr Treat Options Neurol 2006, 8:224-235.
• [14]Birkmayer W, Hornykiewicz O: The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 1961, 73:787-788.
• [15]Cotzias GC, Papavasiliou PS, Gellene R: Modification of Parkinsonism–chronic treatment with L-dopa. N Engl J Med 1969, 280:337-345.
• [16]Müller T: Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms. Int Rev Neurobiol 2010, 95:49-71.
• [17]Frankel JP, Kempster PA, Bovingdon M, Webster R, Lees AJ, Stern GM: The effects of oral protein on the absorption of intraduodenal levodopa and motor performance. J Neurol Neurosurg Psychiatry 1989, 52:1063-1067.
• [18]Gershon MD: Review article: serotonin receptors and transporters – roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004, 20(Suppl 7):3-14.
• [19]Fahn S: Is levodopa toxic? Neurology 1996, 47:S184-S195.
• [20]Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al.: Levodopa and the progression of Parkinson's disease. N Engl J Med 2004, 351:2498-2508.
• [21]Müller T: Motor complications, levodopa metabolism and progression of disease. Expert Opin Drug Metab Toxicol 2011, 7:847-855.
• [22]Müller T: Entacapone. Expert Opin Drug Metab Toxicol 2010, 6:983-993.
• [23]Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A: Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord 2009, 24:541-550.
• [24]Müller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Goetze O, et al.: Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. J Neural Transm 2006, 2006:2006.
• [25]Müller T: Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference. Patient Prefer Adherence 2009, 3:51-59.
• [26]Müller T, Russ H: Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. Expert Opin Pharmacother 2006, 7:1715-1730.
• [27]Parkinson Study Group: Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009, 66:563-570.
• [28]Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, et al.: Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002, 59:408-413.
• [29]Riederer P, Gerlach M, Müller T, Reichmann H: Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease. Parkinsonism Relat Disord 2007, 13:466-479.
• [30]Nyholm D: Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. Clin Pharmacokinet 2006, 45:109-136.
• [31]Smith LA, Jackson MJ: Al Barghouthy G, Rose S, Kuoppamaki M, Olanow W et al.: Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 2005, 20:306-314.
• [32]Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, et al.: Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010, 68:18-27.
• [33]Müller T: The impact of COMT-inhibition on gastrointestinal levodopa absorption in patients with Parkinson's disease. Clinical Medicine Insights: Therapeutics 2010, 2:155-168.
• [34]Dupont E, Andersen A, Boas J, Boisen E, Borgmann R, Helgetveit AC, et al.: Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 1996, 93:14-20.
• [35]Block G, Liss C, Reines S, Irr J: Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997, 37:23-27.
• [36]Alberts JL, Voelcker-Rehage C, Hallahan K, Vitek M, Bamzai R, Vitek JL: Bilateral subthalamic stimulation impairs cognitive-motor performance in Parkinson's disease patients. Brain 2008, 131:3348-3360.
• [37]Berney A, Vingerhoets F, Perrin A, Guex P, Villemure JG, Burkhard PR, et al.: Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients. Neurology 2002, 59:1427-1429.
• [38]Castelli L, Perozzo P, Zibetti M, Crivelli B, Morabito U, Lanotte M, et al.: Chronic deep brain stimulation of the subthalamic nucleus for Parkinson's disease: effects on cognition, mood, anxiety and personality traits. Eur Neurol 2006, 55:136-144.
• [39]De Gaspari D, Siri C, Landi A, Cilia R, Bonetti A, Natuzzi F, et al.: Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2006, 77:450-453.
• [40]Halpern CH, Rick JH, Danish SF, Grossman M, Baltuch GH: Cognition following bilateral deep brain stimulation surgery of the subthalamic nucleus for Parkinson's disease. Int J Geriatr Psychiatry 2009, 24:443-451.
• [41]Klostermann F, Jugel C, Müller T, Marzinzik F: Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm 2012, 119:369-372.
• [42]Grande M, Carrillo IF-F, Palasi A, Valldeoriola F, Santos-Garcia D, De F: Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert. J Neurol
• [43]Houeto JL, Mallet L, Mesnage V, du Tezenas MS, Behar C, Gargiulo M, et al.: Subthalamic stimulation in Parkinson disease: behavior and social adaptation. Arch Neurol 2006, 63:1090-1095.
• [44]Müller T: Drug treatment of non-motor symptoms in Parkinson's disease. Expert Opin Pharmacother 2002, 3:381-388.
• [45]Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al.: Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010, 9:573-580.
• [46]Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, et al.: Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007, 68:1108-1115.
• [47]Lauterbach EC: The neuropsychiatry of Parkinson's disease and related disorders. Psychiatr Clin North Am 2004, 27:801-825.
• [48]Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J: Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. 200.
• [49]Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, et al.: A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009, 72:886-892.
• [50]Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, et al.: Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008, 23:850-857.
• [51]Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E, et al.: Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000, 54:407-411.
• [52]Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al.: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004, 351:2509-2518.
• [53]Barone P, Burn DJ, van Laar T, Hsu C, Poewe W, Lane RM: Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Mov Disord 2008, 23:1532-1540.
• [54]Litvinenko IV, Odinak MM, Mogil'naya VI, Perstnev SV: Use of Memantine (akatinol) for the Correction of Cognitive Impairments in Parkinson's Disease Complicated by Dementia. Neurosci Behav Physiol 2009.
• [55]Juncos JL, Roberts VJ, Evatt ML, Jewart RD, Wood CD, Potter LS, et al.: Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 2004, 19:29-35.
• [56]Yamamura S, Ohoyama K, Hamaguchi T, Kashimoto K, Nakagawa M, Kanehara S, et al.: Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex. Psychopharmacology (Berl) 2009, 206:243-258.
• [57]Weiner WJ: What do clinical trials tell us about treating patients. Parkinsonism Relat Disord 2009, 15:S34-S37.
• [58]Burn DJ, Troster AI: Neuropsychiatric complications of medical and surgical therapies for Parkinson's disease. J Geriatr Psychiatry Neurol 2004, 17:172-180.
• [59]Wolters EC, van der Werf YD, van den Heuvel OA: Parkinson's disease-related disorders in the impulsive-compulsive spectrum. J Neurol 2008, 255(Suppl 5):48-56.
• [60]Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al.: Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010, 67:589-595.
• [61]Olanow CW, Kordower JH, Lang AE, Obeso JA: Dopaminergic transplantation for Parkinson's disease: current status and future prospects. Ann Neurol 2009, 66:591-596.
• [62]Marks WJ, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al.: Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010, 9:1164-1172.